Mosaic Biosciences, Inc. is a company focused on developing biomaterials for tissue engineering applications, particularly synthetic extracellular materials that facilitate natural tissue regeneration. Based in Boulder, Colorado, and incorporated in 2009, Mosaic utilizes its proprietary technology platform to create novel scaffolds with specific biophysical and biochemical properties. These scaffolds are designed for a range of medical applications, including wound healing, bone regeneration, cartilage repair, stem cell therapy, and dermal fillers. The company's innovative approach aims to significantly advance the field of regenerative medicine and support the development of effective solutions for various medical needs. Mosaic Biosciences also collaborates strategically with Catalyst Biosciences to enhance its research and development efforts.
Excellos is a developer and manufacturer specializing in cell and gene therapies, focusing on the advancement of innovative treatments such as CAR-T, tumor-infiltrating lymphocyte therapy, and immunotherapy. The company provides comprehensive development and clinical manufacturing services, which enable clients to harness the full potential of these advanced therapeutics. Excellos emphasizes the delivery of cGMP cellular products and services tailored for scientists and physicians engaged in cell and gene therapy research. By offering expertise in process development and manufacturing, the company aims to accelerate the evolution of cellular therapies, ultimately contributing to enhanced patient outcomes and improved quality of life.
Cell Microsystems, Inc., founded in 2010 and based in Research Triangle Park, North Carolina, specializes in the development and commercialization of products for single cell biology. The company’s proprietary CellRaft™ Technology allows for the efficient sorting and isolation of single cells while maintaining their natural phenotypes and viability under standard culture conditions. This innovative approach enables scientists to select individual cells in real-time and track their progression through imaging, collection, and subsequent analysis. By utilizing this technology, researchers can isolate single cells from small and valuable samples without waste. Cell Microsystems provides scalable solutions that enhance the accessibility of advanced cell separation techniques in laboratories.
Carterra, Inc. specializes in developing and commercializing innovative biomolecular interaction analysis solutions, primarily utilizing label-free technologies. The company offers a range of products, including its MultipleX 96 array-based surface plasmon resonance (SPR) imaging system and the Continuous Flow Microspotter (CFM), which is designed for high-throughput microarray printing. Carterra's services encompass epitope binning and mapping, first-pass kinetics, and assay development, catering to the needs of pharmaceutical and biotechnology clients. Its advanced platforms enable users to conduct kinetic and epitope analysis, supporting the rapid screening of antibodies and identification of potential therapeutic candidates. Founded in 2005 and headquartered in Salt Lake City, Utah, Carterra has additional offices in California, Massachusetts, and Germany, and distributes its products globally, including in China and Japan.
Nivagen Pharmaceuticals, Inc. engages in the development, acquisition, and sales of generic prescription drugs and over the counter products for the North American market. The company sells its products through chain drug stores, regional wholesalers, mass merchandisers, hospitals, GPOs, mail order pharmacies, and other buying groups. Nivagen Pharmaceuticals, Inc. was incorporated in 2009 and is based in Sacramento, California.
Carterra, Inc. specializes in developing and commercializing innovative biomolecular interaction analysis solutions, primarily utilizing label-free technologies. The company offers a range of products, including its MultipleX 96 array-based surface plasmon resonance (SPR) imaging system and the Continuous Flow Microspotter (CFM), which is designed for high-throughput microarray printing. Carterra's services encompass epitope binning and mapping, first-pass kinetics, and assay development, catering to the needs of pharmaceutical and biotechnology clients. Its advanced platforms enable users to conduct kinetic and epitope analysis, supporting the rapid screening of antibodies and identification of potential therapeutic candidates. Founded in 2005 and headquartered in Salt Lake City, Utah, Carterra has additional offices in California, Massachusetts, and Germany, and distributes its products globally, including in China and Japan.
Akoya Biosciences is a spatial biology company offering the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. The CODEX system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials.
Specific Diagnostics, LLC is a medical device company focused on developing innovative solutions for the detection, identification, and antibiotic susceptibility testing of microorganisms. Established in 2011 and based in West Palm Beach, Florida, the company offers the Specific Reveal system, which provides rapid antibiotic susceptibility results. This technology employs a patented low-cost small molecule sensor to streamline laboratory workflows and enhance diagnostic efficiency. By utilizing this system, healthcare providers can quickly assess the effectiveness of antibiotics for treating sepsis and other serious infections, thereby enabling timely and effective patient care. The company’s products ultimately aim to reduce the time between sample arrival and effective therapy selection, addressing the urgent challenge of drug-resistant infections.
Emerging Therapy Solutions, Inc. specializes in the outsourced management of cell and gene therapy treatments for healthcare payers. Founded in 2018 and based in Bloomington, Minnesota, the company provides a range of services including patient management, data collection, analysis, reporting, and claims administration. It focuses on developing proprietary algorithms to address rare conditions, enhancing the efficiency of therapy management. By offering a predictive intelligence platform, Emerging Therapy Solutions aims to simplify the complexities associated with managing emerging therapies, thereby supporting healthcare providers in delivering effective treatment solutions.
Nimble Therapeutics is a developer of a drug discovery platform intended to bring the power of massively parallel chemical synthesis to drug discovery. The company uses its unique maskless chemical synthesis platform to synthesize and systematically discover novel medicines in a variety of therapeutic areas, providing customers aid in the empirical optimization of molecules with more favorable drug-like properties.
Precision Nanosystems develops tools and processes for the development and manufacture of nanoparticles for use as medicines and in medical research. It offers NanoAssemblr benchtop instrument for prototyping of nanoparticles, as well as for the development of nanoparticle-based drugs delivering RNA, small-molecule, and protein therapeutics. The company also provides Neuro9Kit for the study of gene function in neurons and glial cells, as well as potent delivery to primary cells; Test9Kit for the study of gene function in various cell types; and Hepato9Kit for the study of gene function in the liver. In addition, it provides instruments, reagents, and services to the life sciences researchers.
Carterra, Inc. specializes in developing and commercializing innovative biomolecular interaction analysis solutions, primarily utilizing label-free technologies. The company offers a range of products, including its MultipleX 96 array-based surface plasmon resonance (SPR) imaging system and the Continuous Flow Microspotter (CFM), which is designed for high-throughput microarray printing. Carterra's services encompass epitope binning and mapping, first-pass kinetics, and assay development, catering to the needs of pharmaceutical and biotechnology clients. Its advanced platforms enable users to conduct kinetic and epitope analysis, supporting the rapid screening of antibodies and identification of potential therapeutic candidates. Founded in 2005 and headquartered in Salt Lake City, Utah, Carterra has additional offices in California, Massachusetts, and Germany, and distributes its products globally, including in China and Japan.
Aquaro Histology, Inc. is based in Ann Arbor, Michigan, and was founded in 2017. The company specializes in manufacturing a section mounting system designed to enhance the histology workflow in laboratories. Its primary product, the Aquaro ASM, automates the placement of paraffin-embedded tissue sections onto slides, improving workflow efficiency, section quality, and consistency. This compact and user-friendly unit is compatible with existing microtomes, making it a valuable tool for laboratories aimed at enhancing patient diagnosis and care.
RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.
Dynex Technologies, Inc. specializes in the design, engineering, manufacturing, and distribution of fully automated ELISA microplate workstations, laboratory instruments, and related consumables and accessories. The company's products are aimed at enhancing laboratory efficiency and accuracy in various scientific and clinical applications. Dynex Technologies also provides technical support services to ensure optimal use of its equipment. Operating from Chantilly, Virginia, the company serves a global market, distributing its products through a network of distributors across North America, South America, Europe, Asia, the Middle East, and Africa, as well as through online channels. Established in 1952 and formerly known as Dynatech Laboratories, Dynex Technologies has evolved to meet the increasing demands of the laboratory industry, enabling scientists and clinicians to achieve improved health outcomes through advanced detection and automated sample handling solutions.
Medpricer develops a purchased services cost management solution tailored for the healthcare industry. The company's flagship platform, mSource, enables healthcare providers to discover, organize, benchmark, and manage their spending on service providers effectively. By offering precision benchmark reports, project management, and advisory services, Medpricer helps healthcare organizations enhance visibility and control over their expenses. This approach can lead to significant improvements in operating margins, with potential savings of up to 5%. Founded in 2004 and headquartered in Guilford, Connecticut, Medpricer also has an office in Walnut Creek, California. As of October 2019, it operates as a subsidiary of Premier, Inc.
TrakCel's proven technology integrates and orchestrates every aspect of Autologous and Allogeneic supply chains in a scalable, compliant and validated technology platform.
Precision Nanosystems develops tools and processes for the development and manufacture of nanoparticles for use as medicines and in medical research. It offers NanoAssemblr benchtop instrument for prototyping of nanoparticles, as well as for the development of nanoparticle-based drugs delivering RNA, small-molecule, and protein therapeutics. The company also provides Neuro9Kit for the study of gene function in neurons and glial cells, as well as potent delivery to primary cells; Test9Kit for the study of gene function in various cell types; and Hepato9Kit for the study of gene function in the liver. In addition, it provides instruments, reagents, and services to the life sciences researchers.
RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.
PneumRx, Inc. is a medical device company that specializes in developing minimally invasive treatments for patients with emphysema. Founded in 2004 and headquartered in Mountain View, California, the company is known for its RePneu Lung Volume Reduction Coil, an investigational device aimed at improving the quality of life for individuals suffering from this chronic respiratory condition. PneumRx focuses on addressing unmet medical needs in pulmonary medicine through innovative solutions.
ESTECH is a privately held medical device manufacturing and distribution company located in San Ramon, California. The company was founded by Arthur and Raymond Bertolero in 1996 with an emphasis on least invasive products for cardiac surgery. ESTECH has worldwide distribution and has consistently attracted goal oriented professionals who represent the brightest minds in the medical device industry. The in-depth professional experience and tireless dedication of the ESTECH Team has allowed the company to achieve rapid and sustained success in this highly competitive environment. ESTECH is proud of each employee from every department and thanks them for their contribution and support.
AltheaDx, Inc. is a molecular diagnostics company based in San Diego, California, specializing in pharmacogenetics. The company employs an algorithm-based bioinformatics platform alongside a portfolio of pharmacogenomic product tests to aid healthcare providers in determining the most effective medications and appropriate dosing for patients based on their genetic profiles and existing treatment plans. Its IDgenetix test facilitates personalized treatment strategies for common health issues such as cardiovascular diseases, neuropsychiatric disorders, and pain management. Additionally, AltheaDx provides comprehensive research and development services, focusing on molecular biomarker discovery, assay development, and clinical trial support for pharmaceutical and biotech companies. The company serves a diverse clientele, including long-term care facilities, managed care organizations, and individual healthcare providers, thereby contributing to improved patient outcomes through tailored therapeutic decisions.
BioVentrix, Inc. is a medical device company focused on enhancing treatments for congestive heart failure, particularly due to ischemic cardiomyopathy. Founded in 2003 and based in San Ramon, California, the company has developed the Revivent Myocardial Anchoring System. This innovative device aims to improve cardiac function by restoring the size and volume of the left ventricle in heart failure patients. The Revivent system utilizes a hybrid closed-chest transcatheter procedure that involves implanting micro-anchoring pairs in the left ventricle to separate scarred myocardium from healthy tissue, offering a less invasive option for treatment.
ESTECH is a privately held medical device manufacturing and distribution company located in San Ramon, California. The company was founded by Arthur and Raymond Bertolero in 1996 with an emphasis on least invasive products for cardiac surgery. ESTECH has worldwide distribution and has consistently attracted goal oriented professionals who represent the brightest minds in the medical device industry. The in-depth professional experience and tireless dedication of the ESTECH Team has allowed the company to achieve rapid and sustained success in this highly competitive environment. ESTECH is proud of each employee from every department and thanks them for their contribution and support.
ESTECH is a privately held medical device manufacturing and distribution company located in San Ramon, California. The company was founded by Arthur and Raymond Bertolero in 1996 with an emphasis on least invasive products for cardiac surgery. ESTECH has worldwide distribution and has consistently attracted goal oriented professionals who represent the brightest minds in the medical device industry. The in-depth professional experience and tireless dedication of the ESTECH Team has allowed the company to achieve rapid and sustained success in this highly competitive environment. ESTECH is proud of each employee from every department and thanks them for their contribution and support.
Freedom Innovations LLC is a company that offers lower limb solutions for low to high mobility users.
Confirma is the only company that develops and markets an MRI-CAD system, CADstream, revolutionizing MRI study analysis and reporting through automated and standardized processing. CADstream automates the analysis and interventional guidance of MRI studies, providing higher quality imaging studies, lower costs for radiology practices and improved communication tools for physicians and patients. CADstream can be integrated into any workflow scenario and is compatible with all MRI scanners and PACS.
Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in patient management solutions for oncology and genetic disorders. Founded in 2005, Asuragen focuses on the development and commercialization of diagnostic products for clinical laboratories and pharmaceutical partners. Its product portfolio includes a variety of assays for cancer detection and genetic testing, such as the AmplideX FMR1 PCR reagents for fragile X syndrome and the Signature® line of tests for various cancer mutations. The company utilizes patented technologies, including Armored RNA®, to enhance the accuracy and reliability of its diagnostics. Additionally, Asuragen provides testing services and operates a cGMP manufacturing facility, enabling a comprehensive approach to molecular oncology that encompasses discovery, testing, production, and commercialization. Asuragen's commitment to innovation aids the medical community in improving treatment outcomes through precise diagnostic solutions.
AngioScore Inc. is a company that specializes in the development, manufacturing, and marketing of innovative medical devices for the treatment of cardiovascular and peripheral artery diseases. Its primary product, the AngioSculpt Scoring Balloon Catheter, is designed to improve the efficacy of conventional angioplasty procedures. This catheter features a semi-compliant balloon combined with a unique nitinol scoring element, aimed at overcoming the limitations of traditional balloon catheters. By focusing on enhancing endovascular therapy tools, AngioScore addresses critical needs within the interventional market, contributing to advancements in the treatment of vascular diseases.
LDR Holding Corporation develops and markets implantable spine systems and instrumentation for patients and the surgeon community in the United States and internationally. Its spinal surgery solutions include cervical and lumbar artificial disc systems, pedicle screw systems, implant systems, cervical cages, synthetic bone substitutes, and ALIF and TLIF devices, as well as VerteBRIDGE product, a direct lateral and oblique lumbar system for surgical applications. The company offers its products through partnerships with surgeons and distributors in Australia, Argentina, Austria, Belgium, Denmark, Greece, the Netherlands, Italy, Japan, Korea, Mexico, Malaysia, Peru, Portugal, South Africa, Spain, China, Switzerland, Taiwan, Thailand, Turkey, and the United Kingdom. LDR Holding Corporation was formerly known as LDR Spine USA, Inc. and changed its name after acquiring LDR Médical. The company was founded in 2004 and is based in Austin, Texas with additional offices in Troyes, France; Beijing, China; Sao Paolo, Brazil; and Munich, Germany.
PneumRx, Inc. is a medical device company that specializes in developing minimally invasive treatments for patients with emphysema. Founded in 2004 and headquartered in Mountain View, California, the company is known for its RePneu Lung Volume Reduction Coil, an investigational device aimed at improving the quality of life for individuals suffering from this chronic respiratory condition. PneumRx focuses on addressing unmet medical needs in pulmonary medicine through innovative solutions.
Althea Technologies, based in San Diego, CA, is a contract development and manufacturing organization that serves the pharmaceutical and biotechnology industries. The company specializes in cGMP manufacturing, analytical development, and aseptic filling services for both vials and syringes. Althea Technologies also offers gene expression analysis utilizing eXpress Profiling technology and quantitative PCR testing. Additionally, it focuses on the production of microbial-derived recombinant proteins and plasmid DNA, catering to both early-stage and commercial requirements within a single facility.
Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in patient management solutions for oncology and genetic disorders. Founded in 2005, Asuragen focuses on the development and commercialization of diagnostic products for clinical laboratories and pharmaceutical partners. Its product portfolio includes a variety of assays for cancer detection and genetic testing, such as the AmplideX FMR1 PCR reagents for fragile X syndrome and the Signature® line of tests for various cancer mutations. The company utilizes patented technologies, including Armored RNA®, to enhance the accuracy and reliability of its diagnostics. Additionally, Asuragen provides testing services and operates a cGMP manufacturing facility, enabling a comprehensive approach to molecular oncology that encompasses discovery, testing, production, and commercialization. Asuragen's commitment to innovation aids the medical community in improving treatment outcomes through precise diagnostic solutions.
AngioScore Inc. is a company that specializes in the development, manufacturing, and marketing of innovative medical devices for the treatment of cardiovascular and peripheral artery diseases. Its primary product, the AngioSculpt Scoring Balloon Catheter, is designed to improve the efficacy of conventional angioplasty procedures. This catheter features a semi-compliant balloon combined with a unique nitinol scoring element, aimed at overcoming the limitations of traditional balloon catheters. By focusing on enhancing endovascular therapy tools, AngioScore addresses critical needs within the interventional market, contributing to advancements in the treatment of vascular diseases.
Accumetrics is a privately-held company based in San Diego, California, specializing in the development, manufacturing, and marketing of the VerifyNow System. This system comprises a comprehensive suite of assays designed for the assessment of platelet function, which is crucial in various medical applications, particularly in cardiovascular care. Founded in 1996, Accumetrics was initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. The company continues to focus on providing essential tools for healthcare professionals to improve patient outcomes through effective monitoring of platelet activity.
ESTECH is a privately held medical device manufacturing and distribution company located in San Ramon, California. The company was founded by Arthur and Raymond Bertolero in 1996 with an emphasis on least invasive products for cardiac surgery. ESTECH has worldwide distribution and has consistently attracted goal oriented professionals who represent the brightest minds in the medical device industry. The in-depth professional experience and tireless dedication of the ESTECH Team has allowed the company to achieve rapid and sustained success in this highly competitive environment. ESTECH is proud of each employee from every department and thanks them for their contribution and support.